

FDA Online Opioid Summit Reducing the Availability of Opioids Online Meeting Agenda September 9, 2021

9:00 a.m. to 3:00 p.m. (ET), Zoom Virtual Platform	
FDA Moderator	Douglas Throckmorton, M.D., Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research (CDER), FDA
9:00 a.m.	Welcome and Introductory Remarks: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs
9:15 a.m.	Successes and Solutions: Donald D. Ashley, J.D., Director, Office of Compliance, CDER
9:30 a.m.	Patient Health Impact: Panel Discussion
	Libby Baney, J.D., Senior Advisor, Alliance for Safe Online Pharmacies
	 Shabbir J. Imber Safdar, Executive Director, Partnership for Safe Medicines Justin Macy, Pharm.D., J.D., Digital Health Senior Manager, National Association of
	Boards of Pharmacy
10:15 a.m.	Break
10:30 a.m.	Trends and Criminal Cases Updates: Daniel Burke, Chief, Investigative Services Division, Office of Criminal Investigations, FDA
10:45 a.m.	International Perspective: Matthew Nice, Manager, Global OPIOIDS Project, United Nations
11:00 a.m.	New and Novel Analytical Tools
	 Timothy Mackey, MAS, Ph.D., U.C. San Diego
	 Hui Zhao, Ph.D., Smeal College of Business, Pennsylvania State University
11:30 a.m.	Lunch
12:30 p.m.	Concurrent Roundtable Breakout Sessions
	Moderators: S. Leigh Verbois, Ph.D., Director, Office of Drug Security, Integrity, and
	Response (ODSIR), CDER
	Sangeeta V. Chatterjee, Pharm.D., Deputy Director, ODSIR, CDER
	What are examples of stakeholder successes?

- What is the current and evolving landscape?
- What are the gaps and challenges?
- What are novel tools, technologies, and approaches to addressing the problem?

1:30 p.m. Break

1:45 p.m. Concurrent Roundtable Breakout Sessions (continued)

2:30 p.m. Breakout Sessions Recap: S. Leigh Verbois, Ph.D.; Sangeeta V. Chatterjee, Pharm.D.

2:45 p.m. Adjourn and Closing Remarks: Donald D. Ashley, J.D.